[Retracted] Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression

Table 3

Comparison of adverse events (n (%)).

	Conventional group (n = 40)	Experimental group (n = 40)	x^2	value
White blood cell decline	5	0
Liver function impairment	4	0
Skin rash	2	4
Pruritus	1	3
Neutropenia	3	0
Total incidence (%)	15 (38%)	7 (18%)	4.013	0.045